Peer-influenced content. Sources you trust. No registration required. This is HCN.

Clinical Advances in Hematology & OncologyThe Emerging Role of Pirtobrutinib in Chronic Lymphocytic Leukemia

In this interview, Nicole Lamanna, MD, discusses challenges and application of BTK inhibitors, results with pirtobrutinib in hematologic malignancies, specifically addressing CLL, and shares her personal observations regarding pirtobrutinib use.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form